Performance of CADM1, MAL and miR124-2 methylation as triage markers for early detection of cervical cancer in self-collected and clinician-collected samples: an exploratory observational study in Papua New Guinea

Monica Molano,Dorothy A Machalek,Grace Tan,Suzanne Garland,Prisha Balgovind,Gholamreza Haqshenas,Gloria Munnull,Samuel Phillips,Steven G Badman,John Bolnga,Alyssa Marie Cornall,Josephine Gabuzzi,Zure Kombati,Julia Brotherton,Marion Saville,David Hawkes,John Kaldor,Pamela Josephine Toliman,Andrew John Vallely,Gerald L Murray

DOI: https://doi.org/10.1136/bmjopen-2023-081282

IF: 3.006

2024-06-21

BMJ Open

Abstract:Objective WHO recommends human papillomavirus (HPV) testing for cervical screening, with triage of high-risk HPV (hrHPV) positive women. However, there are limitations to effective triage for low-resource, high-burden settings, such as Papua New Guinea. In this exploratory study, we assessed the performance of host methylation as triage tools for predicting high-grade squamous intraepithelial lesions (HSIL) in self-collected and clinician-collected samples. Design Exploratory observational study. Setting Provincial hospital, same-day cervical screen-and-treat trial, Papua New Guinea. Participants 44 hrHPV+women, with paired self/clinician-collected samples (4 squamous cell carcinomas (SCC), 19 HSIL, 4 low-grade squamous intraepithelial lesions, 17 normal). Primary and secondary outcome measures Methylation levels of CADM1, MAL and miR124-2 analysed by methylation-specific PCRs against the clinical endpoint of HSIL or SCC (HSIL+) measured using liquid-based-cytology/p16-Ki67 stain. Results In clinician-collected samples, MAL and miR124-2 methylation levels were significantly higher with increasing grade of disease (p=0.0046 and p<0.0015, respectively). miR124-2 was the best predictor of HSIL (area under the curve, AUC 0.819) while MAL of SCC (AUC 0.856). In self-collected samples, MAL best predicted HSIL (AUC 0.595) while miR124-2 SCC (AUC 0.812). Combined miR124-2/MAL methylation yielded sensitivity and specificity for HSIL+ of 90.5% (95% CI 69.6% to 98.8%) and 70% (95% CI 45.7% to 88.1%), respectively, in clinician-collected samples, and 81.8% (95% CI 59.7% to 94.8%) and 47.6% (95% CI 25.7% to 70.2%), respectively, in self-collected samples. miR124-2/MAL plus HPV16/HPV18 improved sensitivity for HSIL+ (95.2%, 95% CI 76.2% to 99.9%) but decreased specificity (55.0%, 95% CI 31.5% to 76.9%). Conclusion miR124-2/MAL methylation is a potential triage strategy for the detection of HSIL/SCC in low-income and middle-income country.

medicine, general & internal

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the effectiveness of using methylation of CADM1, MAL and miR124 - 2 as triage markers for early detection of cervical cancer in Papua New Guinea, a low - income country. Specifically, the study focuses on the performance of these markers in self - collected samples and doctor - collected samples, especially their ability in predicting high - grade squamous intraepithelial lesions (HSIL). The research background is that the World Health Organization recommends using human papillomavirus (HPV) tests for cervical screening and further triaging women who are positive for high - risk HPV (hrHPV). However, in areas with limited resources and a heavy disease burden, such as Papua New Guinea, effective triage methods still face challenges. Therefore, this study aims to explore whether these molecular markers can be used as a potential triage strategy to improve the efficiency and accuracy of early detection of cervical cancer in low - and middle - income countries (LMICs).